Other innovations
If your innovation doesn’t fit any of the active categories then this is the place to submit your innovation for feedback and the opportunity for wider adoption across the region.

Ideas (Wealth creation)

Innovation 'Elevator Pitch':
OsCare Sono allows early assessment of Osteoporosis risk in an out of hospital environment. It is a low cost device, can be used by any healthcare professional, emits no radiation, proven technology & vastly improved patient outcomes and cost savings
Overview of Innovation:
The OsCare Sono™ measures ultrasound wave propagation longitudinally in the radial bone. In comparison to other ultrasound bone sonometers, the OsCare Sono™ has a lower ultrasound frequency, of about 200 kHz. The low frequency ultrasound travels deeper in to the bone tissue providing better correlation with cortical thickness and its patented transducers and algorithms help to eliminate the effect of soft tissue. Oscare Sono also uses the radial bone which is easier to access and more sensitive to osteoporotic changes.

The device compares the measurement result to the available reference population group data and calculates the Z- and T-Score values, indicating if the patient has an increased risk of osteoporosis and future fractures.
OsCare Sono™ measurement results help to recognize those individuals who are at higher risk for osteoporosis and potentially further investigations such as a DEXA.
Osteoporosis is an increasingly prevalent skeletal disease characterized by diminished bone strength and increased risk of fracture which costs the NHS £2.9bn annually.

‘The International Society of Clinical Densitometry (ISCD), the International Osteoporosis Foundation (IOF) and the European Society for Clinical and Economical Aspects of Osteoporosis and Osteoarthritis (ESCEO) describe in their position statements that although DXA (dual X-ray absorptiometry) and the femoral neck are the reference technology and site for diagnosing osteoporosis, other techniques such as quantitative ultrasound (QUS) can be used in clinical practice to identify patients at high or low risk of having osteoporosis. The Foundation and Societies stated that QUS is proven to predict osteoporotic fractures similarly to central DXA.’

Oscare Sono is highly portable and can be set up within minutes in an environment suitable for assessing patients.
No ionising radiation is emitted and therefore there is no restriction on location or IMIR regulations.

Early assessment of patients at risk of Osteoporosis in the NICE pathway will identify patients at risk of osteoporosis and allow early intervention.
Oscare will enable large scale assessment of patients at risk of Osteoporosis, facilitate early intervention and improve patient outcomes.
Stage of Development:
Market ready and adopted - Fully proven, commercially deployable, market ready and already adopted in some areas (in a different region or sector)
WMAHSN priorities and themes addressed: 
Long term conditions: a whole system, person-centred approach / Wellness and prevention of illness / Wealth creation / Clinical trials and evidence / Digital health / Innovation and adoption / Person centred care
Benefit to NHS:
Features:
  • Low-frequency (200 kHz) axial ultrasound velocity correlates well with bone mineral density (BMD) and cortical thickness, giving valuable information on bone strength
  • No ionizing radiation — measurement can be performed in any suitable location and repeated when required
  • Facilitates assessment in any appropriate setting, GP surgery, pharmacy etc.
  • Short assessment time, typically 10 minutes per patient
  • OsCare Sono™ is cost-effective and enables large scale assessment – A reliable and quick procedure
  • No specialised or qualified staff needed, short training cycle, easy to interpret report.
  • Measurement is on the radial bone which is easily accessible so no need for patients to undress
  • Patented soft tissue disturbance effect eliminates artefact producing a clear signal and improved diagnostic confidence
  • Compact in size & highly mobile. No dedicated PC needed, software runs in a standard Windows operating system
Cost savings from:
  • Reduction of referrals for DEXA scanning
  • Potentially significant cost savings in treating reduced numbers of fractures
  • Reduced demand on downstream services as 70% of patients with #NOF or pelvis fail to make a full recovery
  • Reduced emergency admission for osteoporotic fractures
The International Society of Clinical Densitometry (ISCD), the International Osteoporosis Foundation (IOF) and the European Society for Clinical and Economical Aspects of Osteoporosis and Osteoarthritis (ESCEO) recognize QUS methods as relatively inexpensive, transportable and proven to predict osteoporotic fractures as well as the central DXA. Compared to DXA, the OsCare Sono™ device is significantly less expensive, portable and, importantly, free of potentially harmful ionizing radiation.

Return on Investment
  • NHS Osteoporotic fracture burden is £2.9 or 3.5 Bn, depending on source
  • Identifying patients who may be at risk or actually have osteoporosis is not being undertaken currently at the rate which is needed. As the population ages, this will become more significant
  • The device is 80% the cost of one A&E admission
  • Early identification reduces decades of patient treatment costs
Initial Review Rating
5.00 (2 ratings)
Benefit to WM population:
Early assessment of patients will facilitate early identification of patients at risk of osteoporosis and enable early intervention. This will lead to reduced incidence of osteoporotic fractures, related mortality and morbidity and associated health costs.
It will dramatically improve patient outcomes by reducing the significant mortality and morbidity associated with osteoporosis which is frequently overlooked as a consequence of being older rather than a modifiable outcome - which it is.
There are currently not enough DEXA scanners in the West Midlands region to cope with demand.
The adoption of this technology within the West Midlands and across the UK. Would not only save some patients the inconvenience of going for a DEXA scan or even repeated scans, when they are not required whilst still providing the patients with confidence and reassurance.
This is not intended as a replacement for DEXA which is still the gold standard in diagnosis of Osteoporosis. This would mean that patients referred for DEXA scanning would have a higher diagnostic yield.
This in turn would reduce the costs of DEXA referrals and investigations for GPs/CCGs to where they are required thereby reducing the waiting times for such investigations and the costs and time associated with reporting negative results on the imaging consultation service and the GP on a subsequent patient visit to collect results.
It is estimated that Oscare Sono will facilitate a reduction of DEXA referrals which cost in the region of £278 per patient. The total number of DEXA scans undertaken in the region and the outcome is not known. But it is clearly not enough as many thousands of patients suffer osteoporotic fractures still and this number will continue to rise as the population ages.
Physiological Measurements Ltd are working closely with the Finnish inventors or this product and have secured a UK distribution and support agreement. The regional and wide scale adoption of this technology would allow the company to grow and take on additional specialist staff to train and support users of this technology as well as having a significant impact on the company and West Midlands Osteoporosis services.
Current and planned activity: 
The device and concept are a disruptive innovation and are not currently in place within the UK healthcare system.
We are about to start a small scale trial with a GP in the Northwest of England and a Pharmacy in the Midlands to gauge acceptance and identify how many people in a cohort are found to be at risk. We are contacting lead commissioners and clinical leads at each of the 44 CCGs that we are currently delivering services too.

Planned / required activity:
  • Procurement / Adoption of our OsCare Sono – First Line Osteoporosis Assessment technology -  We seek to disseminate via the network to clinicians at all levels, the potential impact of this innovation in terms of improved patient outcomes and a reduction on healthcare resource use at all levels.
  • Evaluation / Validation / Clinical Trial  - We would welcome the opportunity to work with an acute NHS trust to evaluate the impact this innovation could have on patient flow and also as a primary prevention tool.
What is the intellectual property status of your innovation?:
Patented Product held by Oscare Medial OY, Finland

Product Certification: CE IIa ref:0537 - - EC-Certificated 93/42/EEC - ISO13485:2003
Return on Investment (£ Value): 
Very high
Return on Investment (Timescale): 
0-6 mon
Ease of scalability: 
Simple
Read more
Hide details
Jon 08/02/2016 - 17:14 Publish Login or Register to post comments
4.2
5
Votes
-99999
Innovation 'Elevator Pitch':
​LIAISE is a cloud-based platform that harvests information from publicly available and third party sources and auto-combines with your own spreadsheet data to identify accessible efficiencies 
Overview of Innovation:
In an ideal world, cash would be available for investment in new services and models of care.
 
In reality, however, almost all of next year’s fund - £1.8bn of it – will be spent on bailing out NHS providers in deficit, leaving just £339m to fund ‘transformation'
 
With this in mind and alongside the Lord Carter of Coles' report on Adjusted Treatment Cost (ATC) we have been conscious that Trusts need some help in unpicking what this all might mean for them.
 
The Health Service Journal analysis published on January 5th gave you a potential savings figure using reference costs.
 
Several observers have commented that they were expecting something a little more sophisticated. 
 
We’d like offer you a share of the benefits achieved with other NHS Trusts and public sector bodies by use of our LIAISE platform.
 
Others have commented how we have brought into clear view a number of savings opportunities that were hidden - even though they can be identified from a sophisticated analysis of publicly-available data and cross comparison to in house spreadsheet data
Stage of Development:
Market ready and adopted - Fully proven, commercially deployable, market ready and already adopted in some areas (in a different region or sector)
WMAHSN priorities and themes addressed: 
Wealth creation / Innovation and adoption / Person centred care
Benefit to NHS:
  • Avoid un-necessary consultancy costs
  • Unlock dead budget
  • Self supported business improvement
  • Accurate management information
  • Reduce spreadsheet dependency / and single points of failure
  • Reduce lost time (FTE days)
Initial Review Rating
4.20 (1 ratings)
Benefit to WM population:
Reduction in bottom line costs without the need for outsourcing or redundancies
More available cash to pay for transformation and future health care system jobs
Current and planned activity: 
We have worked with Bradford District Care Trust, Heart of England NHS Foundation Trust and have proposals in with Sandwell and West Birmingham NHS Trust. Our ROI is between 3,000 and 10,000%. IE for every pound spent we will model £3 - £10k of savings
Demonstrations of capability provided;
  • St Andrews Healthcare – We have just undertaken a high level demonstration  benchmarking suggesting achievable targets of between £4 and 26 million which is representative of 2 – 14% against an income of £189m
  • Bradford District Care trust Estates Department - We have benchmarked the ED against direct comparators and demonstrated £140k to £2m which is representative of 1% and 14%
  • Heart of England NHS FT - We have benchmarked the ED against direct comparators and demonstrated  procurement savings of £910k and operational efficiencies of between £265k and £9m which would is equivalent to a 6400% ROI. Assuming £4.5m / 50% of savings are realised
What is the intellectual property status of your innovation?:
Fully owned by Alphafish associates
Return on Investment (£ Value): 
Very high
Return on Investment (Timescale): 
0-6 mon
Ease of scalability: 
Simple
Regional Scalability:

We are concentrating our efforts on sales in the UK with an initial focus on the NHS and specifically the 38,000 managers who have an immediate need to find efficiencies totalling £22bn with a government investment of £8bn. We will expand into the entire public sector and then beyond into the $2.7bn global market as defined by Gartner
 
Analysts to Discuss Business Intelligence Trends at Gartner Business Intelligence and Information Management Summit 2013, June 10-11 in Mumbai, India. Worldwide business intelligence (BI), corporate performance management (CPM) and analytics applications/performance management software revenue totalled $13.1 billion in 2012, a 6.8 percent increase from 2011 revenue of $12.3 billion, according to Gartner, Inc.

From the experience we have to date there is considerable opportunity for Cloud CIO in the UK before venturing to Europe and the East Coast of the USA. 
 

Measures:

We believe we can build a cost down business model that helps the NHS to reduce consultancy costs by 30%, saving the NHS a potential £100m million per year.

 

Adoption target:

Market Share – NHS managers only 
User licenses @ £2k (min 10 users)

  • 5% = £3.7m
  • 10% = £7.4m

Upsell 1, auto-combine own systems based on 50% of users @ +1k per pack 

  • 5% = £0.9m
  • 10% = £1.85m

Upsell 2, 30% professional services

  • 5% = £1.1m
  • 10% = £2.2m

Total

  • 5% = £5.7m
  • 10% = £11.9m
Read more
Hide details
Neil Streets 29/01/2016 - 11:44 Detailed Submission Login or Register to post comments
4.7
3
Votes
-99999
Innovation 'Elevator Pitch':
Neurocare’s™ muscle stimulation  therapy is safe, comfortable, non-invasive and clinically proven to accelerate  wound healing and musculoskeletal  rehabilitation which enables major treatment  cost reduction with  significant increases in HRQoL.
Overview of Innovation:
Neurocare™are seeking to promote the adoption in the UK of their muscle stimulation device and its comprehensive treatment protocols .
 
Neuromuscular electronic stimulation therapy is well established in many countries in the world particularly in the U.S.A. and with six FDA indications has a strong clinical trial evidence base in most of its  applications.  The Canadian and American Health Authorities have recommended its use in healing pressure ulcers as did the EPUAP/NPUAP collaboration in work published in 2009.
 
Patient compliance is potentially a challenge particularly where adherence to a treatment programme over a period of time is necessary. Many muscle stimulation devices can be painful  when set at voltages required to achieve a therapeutic level of muscle recruitment.
 
The Neurocare™ device has a unique electronic configuration which features AC output and allows very high voltage for full muscle recruitment at very low amperage for pain free comfortable therapy. Whether treatment occurs in clinic or in the home the objective is to recruit the patient as an enthusiastic active participant in their own programme of therapy.
 
The Neurocare™ device functions by introducing an electrical signal into the motor nerve of the muscle causing a muscle contraction which replicates exercise whilst activating the peripheral arterial and vascular systems which are essential to moving freshly oxygenated blood through the wound site.
 
Each treatment lasts between 30 to 45 minutes and may be administered once or twice daily as necessary at a cost of approximately £2 per treatment.
 
As an option remote web-based management incorporating a “virtual clinic” allows home self-treatment without the presence of healthcare professionals facilitating much more intensive therapy than periodic clinic/outpatient visits allow. This has potential for substantial cost reductions and significant acceleration of healing wounds or musculoskeletal rehabilitation with consequent improvement in HRQoL and timescales reduction.
 
Stage of Development:
Market ready and adopted - Fully proven, commercially deployable, market ready and already adopted in some areas (in a different region or sector)
WMAHSN priorities and themes addressed: 
Long term conditions: a whole system, person-centred approach / Wealth creation / Clinical trials and evidence / Innovation and adoption
Benefit to NHS:
As an adjunct therapy, NMES devices have been shown in clinical studies to reduce healing timescales compared with existing treatment pathways.  This is true of wound healing and musculoskeletal rehabilitation in general.
 
The Neurocare™  device is  simple,safe, non-invasive and comfortable. It is suitable for use in hospitals, clinics and the home and can be self-administered which permits both logistically and financially very much more intensive therapy than could be achieved with multiple visits to a clinic for outpatient treatment.
 
With the addition of the web-based management system the patient and Healthcare Professional can maintain constant contact for monitoring and management of the patient’s progress thus minimising the frequency of outpatient visits.
 
As an example diabetic ulcers are known to be slow healing. Six months plus  would be typical and many endure well in excess of one year. An adjunct therapy which can reduce  healing timescales by 25%+ and in many cases avoid patient episodes such as  revascularisation and amputation clearly reduces costs and radically improves the outcome for patients.
 
Many of the documents attached evidence the potential improvements accessible with this therapy which is very versatile and will bring more effective resource utilisation, cost reduction and improved patient outcomes across its very broad range of applications.
 
Web-enabled home self treatment accords well with NHS strategic priorities which stress the objective of bringing treatment closer to the patient and highlight the increasing importance of improving the patient experience.
 
Once established as a cost effective way of achieving wound healing the concept of using web-enabled treatment would be extended on a broad front. With NMES an extensive range of medical conditions can be treated remotely. The use of the Internet and the “Virtual Clinic” staffed by multi disciplinary experts allows scarce expert resources to be active over very large patient populations whilst simultaneously permits the patient to remain under the general care of their GP Practice.
Initial Review Rating
3.80 (3 ratings)
Benefit to WM population:
A healthy population is likely to be more productive than an unhealthy one and increasing productivity creates increasing wealth per capita. Healthcare delivered in the most productive way means that for each resource unit consumed more units of healthcare can be delivered.
 
Incremental productivity gains are largely driven by innovation but if maximum value is to be gained  proven innovation must be rapidly adopted and diffused.
 
Today’s aging population is increasingly frail and high quality care is increasingly expensive . Expectations will not be met if innovation driven productivity improvement stalls.
 
In a definitive NHS Document entitled ”Innovation Health and Wealth” published in Dec 2011, Innovation is defined as “An idea service or product new to the NHS or applied in a way that is new to the NHS, which significantly improves the quality of health and care wherever it is applied”. To this end the document recommends inter alia that the NHS should strive  to embrace innovation and become an early adopter, should make full  and early use of digital technologies and increasingly shift focus  toward early diagnosis and prevention,
 
The innovation proposed in this document accords well with these aspirations in that we are proposing the widespread adoption and diffusion of a clinically proven but as yet sparsely adopted medical technology supported by a state of art web-based management system.
 
Healing diabetic ulcers with home self-treatment has been chosen to illustrate the potential of web enabled management of NMES therapy  in this document but the same principles may be applied wherever this form of therapy has proven efficacy.
 
Effective prevention is difficult to prove clinically but several trials have shown that pressure ulcers can be prevented using NMES and the restoration of muscle strength and balance may extend self sufficient independence and thus delay nursing home and/or inpatient costs.
 
The way is open for CCGs to finance adoption trials at relatively low cost and risk pending widespread diffusion.
 
Current and planned activity: 
We are working with
1). Prof. Michael Edmonds at the Diabetic Foot Clinic - Kings College London.
2). Mr. David Russell at the Limb Salvage Clinic - Leeds NHS Trust
3). Prof. Ian Chetter - Vascular Surgeon at Hull NHS Trust

preparing an application for RfPB.

We also recently participated with other NHS hospitals & their Test Beds applications. We are continuing work with the Leeds Academic Health Network.
 
We are currently also working with four further AHSNs; East Midlands, West Midlands, West of England, Yorkshire and Humber.
  • Evaluation / Validation / Clinical Trial - Need to gain additional validation of system within the UK – Thus seeking a trial centre.
    Leading to:
  • Procurement / Adoption - Require addition assistance and validation to support UK sales and marketing to UK treatment centres within Acute and Primary sectors
What is the intellectual property status of your innovation?:
The device IP belongs to Neurocare Europe Limited under license from Neurocare  Inc USA.  
Return on Investment (£ Value): 
Very high
Return on Investment (Timescale): 
1 year
Ease of scalability: 
Simple
Read more
Hide details
Patricia Forrester 22/01/2016 - 15:45 Publish 1 comment
3.6
5
Votes
-99999
Innovation 'Elevator Pitch':
myCOPD is the first step for patients in having their COPD pathway online. 98% of patients had their inhaler technique corrected with no clinical interaction with myCOPD.
Overview of Innovation:
myCOPD is a complete online self-management solution for patients with COPD. Developed under a £1millon NHS contract, myCOPD was selected by Sir Bruce Keogh for the NHS Innovation Accelerator Programme.
https://mycopd.mymhealth.com
https://mypulmonary.rehab
myCOPD is able to deliver the expertise normally provided by the consultant, nurse, physiotherapist, pharmacist and even psychologist at a time and place to suit the patient.
Built by clinicians and tested with patients, myCOPD delivers a simple, functional user interface that can be accessed on any device that connects to the Internet from smartphones and tablets to laptops and desktop computers delivering advanced patient self-management, education, pulmonary rehabilitation and disease management at an individual and population level.
myCOPD brings together patients and clinicians in a single, integrated platform delivering an interface for the clinician managing a population of patients with COPD. The clinician dashboard allows the prompt identification of patients with worsening symptoms. Allowing clinicians to monitor their population more efficiently and allocate resources more appropriately. 
myCOPD is scalable, fully language and region translatable allowing the application to be used in multicultural communities and wider markets in Europe and beyond.

myCOPD has proven to correct 98% of inhaler errors (present in over 90% of patients) with no other clinical intervention.

Patient features
  • An interface where patients can feedback their symptoms and quality of life scores to their health care provider
  • Online self-management plan
  • Patient education
  • Online inhaler diary
  • Oxygen alert card
  • Inhaler technique videos
  • Comprehensive online pulmonary rehabilitation program
Clinician features
  • Community/Exacerbation Review
  • Primary Care Review
  • Secondary Care Review
  • Oxygen Assessment
  • Spirometry
  • Medicine use review
  • Upload any document
Stage of Development:
Market ready and adopted - Fully proven, commercially deployable, market ready and already adopted in some areas (in a different region or sector)
WMAHSN priorities and themes addressed: 
Long term conditions: a whole system, person-centred approach / Wellness and prevention of illness / Wealth creation / Clinical trials and evidence / Digital health / Innovation and adoption / Person centred care
Benefit to NHS:
There is no cure for COPD and good symptom management is essential to stablise disease and prevent recurrent flare-ups or exacerbations. Exacerbations often require intensive treatment and can be severe enough to require hospital admission. COPD is associated with considerable costs, both to the NHS and to society. COPD is the second most common reason for emergency admission to hospital, accounting for one in eight non-elective admissions1. In England in 2012-2013, there were 121,836 admissions for COPD of which the vast majority (95%, n=115,814) were emergency admissions.
From a clinical standpoint, the benefits of systematic symptom documentation, explicit care planning, improved inhaler technique, improved adherence and better access to pulmonary rehabilitation can all be expected to yield improved disease control. The myCOPD system has been evaluated and each individual component has been shown to reduce the likelihood of an acute exacerbation or allow it to be identified early enough to avoid hospital admission. This has clear cut economic benefits.
Prior to going onto myCOPD, over 90% of patients were not able to use their inhalers properly, after 3 months with no clinical interaction the patients were re-evaluated. The result was that 98% of patients were then able to use their inhalers properly with no clinical errors. 95% of patients improved their CAT score. The cost of medicines wastage to the NHS runs well into the millions, add on the fact that patients are not able to take their medications we are wasting money on medications on a large scale.
Now if patients were able to take their inhalers properly and we start to see the drug trial results with exacerbation reduction by around 25%, the savings would be on a large scale. There is an economic evaluation attached which was completed by a third party prior to our SBRI Phase II application for detailed cost savings.
When it comes to Pulmonary Rehabilitation, we are able to provide this at 100th of the cost of current channels.
 
Online Discussion Rating
4.83 (6 ratings)
Initial Review Rating
4.80 (2 ratings)
Benefit to WM population:
We believe that self-management should begin at the point of diagnosis. We need to put the right tools in the patient’s hands at the start of their pathway, not at the end, not in the middle or somewhere in between, but at the start. Mortality in COPD is high, patients do not want to go to hospital and will often turn to the internet when they need answers about their disease. For most of us, our lives are managed online – banking, shopping, to name a few but not our health, for now. Having a better-educated COPD population, that can access the information they need and more, which has been written by NHS respiratory specialists, will ensure patients understand their disease like never before. Are able to keep track of symptoms and medicines usage. What we will start to see is a better informed patient population, that understands when their CAT scores are getting higher they need to start their rescue pack – that will not only save a nurse/GP appointments but help the patients recover quicker.
Pulmonary rehabilitation (PR) is delivered at a dictated time, day and place – thus resulting in only 5-7% of the eligible COPD population being able to access PR. For the first time the WM population will have the option of opting to do their classes either face to face through the traditional channels, or online or as part of a blended programme where they can access both face to face and digital. Thus delivering real patient choice to how and where they receive their rehab care. 

 
Current and planned activity: 
Back in July, Sir Bruce Keogh announced after a global calling that they had selected 17 proven technologies to be rolled out at scale across the NHS, in line with the vision of the Five Year Forward View. myCOPD was one of them and the only respiratory selection. Over the last 6 months we have been working with many senior figures across the NHS to uncover the barriers and real drivers for change. We have focused our activities with aligned AHSNs and the largest COPD based CCG populations. We want to raise awareness that a digital self-management solution is now available for those with COPD, the aim is to get the solution commissioned across CCGs so all patients are able to access it.
 
Return on Investment (£ Value): 
Very high
Return on Investment (Timescale): 
0-6 mon
Ease of scalability: 
Simple
Regional Scalability:
The innovation is easily and readily scalable. All data that feeds into myCOPD sits on servers at Portsmouth NHS Trust on the N3 network. As this is an online solution, scalability is not an obstacle, it has been built on Cassandra databases which means linear scaling is infinite - these are the same platforms Netflix, Google and other use. When a CCG has full access to myCOPD it is easy to create user/patient accounts - with the click of a button.
 
We have not scaled in any other area - we have only been fully ready for market since December 2015.
 
Measures:
The outcomes are reductions in hospitals admissions, re-admissions, increased access to pulmonary rehab, increased completed number of pulmonary rehab attendees, a significant improvement in inhaler/medication adherence, improvement with inhaler technique.
 
Imbedded within the programmes for the patients is the COPD Assessment Test (CAT). Which is a patient-completed instrument that complements existing approaches to assessing COPD impact. It has been designed to provide a simple and reliable measure of health status in COPD and assists patients and their physicians in quantifying the impact of COPD on the patient’s health. 
The CAT has undergone a rigorous, scientific development process and the first validation studies show that it has properties very similar to much more complex health status questionnaires such as the St George’s Respiratory Questionnaire (SGRQ) that are used in research studies. It takes only a fraction of the time to complete, however, making it suitable for routine use. It is and has been used in COPD studies in Europe, USA and Asia. 
 
Year on year admissions into hospital with COPD are increasing, the impact the solution makes on the patient population can be measured through past admissions data Vs. patients on myCOPD and looking at re-admissions data.
 
Adoption target:
Is for 3-5 CCGs in the WM provide access for patients to both myCOPD and myPR within the next 12 months. This will provide access to at least 6,000 patients. It can used within the community, primary care and secondary care teams. There is currently a complete abscence of relaible tools for patients and clinicians in the digital space for COPD.
Read more
Hide details
Ian Thompson 11/01/2016 - 12:28 Sign Posted 12 comments
0
0
Votes

Innovation 'Elevator Pitch':
Software that automatically engages with stakeholders to track performance & risk and identify continuous improvement opportunities in campaigns and/or contracted out services.
Overview of Innovation:
Do you find it difficult to track and measure contract or campaign performance? Compared to well-managed contracts/campaigns, unmanaged or poorly managed contracts/campaigns can lead to costly inefficiencies, poor performance and an increase in risk.
ContractsWise is now offering its innovative, cloud-based contract management tool: ECMS, (available via the Crown Commercial Services G-Cloud Framework Agreement if required). Designed by experienced contract managers, ECMS can increase performance and savings, improve service quality, and mitigate risk, with an automatically backed-up database to prevent loss of data.
Some of ECMS’s features include:
  • A  register to record all contracts/campaigns and associated documents in a secure database
  • A dashboard that can be individually configured for each user, with information on performance and risks
  • Compatibility with any device with a web-connection, including tablets and smartphones, without the need to download additional software
  • Actively and automatically engage with stakeholders.
For those who don’t need all of ECMS’s features, there’s ECAS, an administration system that is scalable to your needs and will help improve control of information and documentation.
ECAS’s Entry Level Plan features include:
  • Searchable database of your information and documents
  • Automated reminders for important dates
  • Secure cloud storage with automated data back-up which frees up physical space
  • Archive old information
  • Online tutorials and help documents.
All of ECAS’s features are included in ECMS.
Understanding contract management and how to improve performance can be difficult, which is why ContractsWise also run an online training course: An Introduction to Contract Management, which combines theory and best practice to give you a comprehensive understanding of the subject.
For more information on the ways that ContractsWise can help please visit www.contractswise.com
Stage of Development:
Market ready and adopted - Fully proven, commercially deployable, market ready and already adopted in some areas (in a different region or sector)
WMAHSN priorities and themes addressed: 
Mental Health: recovery, crisis and prevention / Long term conditions: a whole system, person-centred approach / Advanced diagnostics, genomics and precision medicine / Wellness and prevention of illness / Education, training and future workforce / Wealth creation / Clinical trials and evidence / Digital health / Innovation and adoption / Patient and medicines safety / Person centred care
Benefit to NHS:
There is an increasing body of evidence that shows that organisations incur significant unplanned costs, don't achieve expected savings or service quality as a result of a lack of effective contract/campaign management.
Research by the International Association of Commercial and Contract Management (IACCM) has quantified the value of these losses at the equivalent of 9.2% of revenue.
All organisations want to achieve the maximum value for every pound spent but in the NHS this is critical. ContractsWise provides low cost tools that will enable the NHS ensure that best value is achieved, risks are identified and mitigated and opportunities for continuous improvement are identified.
A business case template is available to download for free from our website www.contractswise.com and the return on investment will include: avoidance of unplanned costs; never miss a contract termination or renewal negotiation opportunity; realise planned cost savings or revenue improvements; reduce administration time; improve internal and external stakeholder relationships; redice risks; improve compliance; improve reporting.
Initial Review Rating
3.80 (1 ratings)
Benefit to WM population:
Users of the NHS in the West Midlands will receive improved services and will be able to contribut eto the continuous improvement of services.
Providers of services will have greater control over their budgeted expenditure or revenue.
Current and planned activity: 
Our software has recently been adopted by Western Sussex NHS Trust.
Following a full review of software available on the market The Chartrered Institute of Procurement and Supply (CIPS) chose our software and has been operating with it since February 2015.
Return on Investment (£ Value): 
Very high
Return on Investment (Timescale): 
0-6 mon
Ease of scalability: 
Simple
Regional Scalability:

Being cloud based with minimal training required,the software can be easily scaled nationally and internationally.

Measures:

The goal is to maximise the performance and minimise the risks associated with the delivery of services by a 3rd party. Maximising performance will ensure that value for money is also maximised and will increase end user satisfaction rates. Minimising risks will reduce the possibility of unplanned costs that have not been budgetted for and will help ensure that any planned savings are actually delivered.
Users of the software will be able to continually measure performance and risk using the tools and dashboard built into the software. The users have full control over what it wants to measure so these can include quality, safety, cost and people.
ContractsWise limited will also measure the satisfaction of our customers through engagement with key stakeholders and work with them to maximise the benefits achieved by using the software in order to generate compelling case studies.

Adoption target:

Any organisation, part of an organisation or project whose measure of success relies upon the delivery of services from one or many 3rd parties.

Read more
Hide details
Noel Green 14/12/2015 - 15:53 Detailed Submission Login or Register to post comments
2.8
4
Votes
-99999

Recent Activities

MindHarp has been moved from Initial Submission to Publish 1 week 1 day ago
Dementia Dekh Bhaal has been moved from Initial Submission to Publish 2 weeks 6 days ago
Hesham Abdalla commented on Hexitime- The Skill Exchange and Timebank for Improving Healthcare 3 weeks 6 days ago
Knowing Me! has been moved from Initial Submission to Publish 1 month 3 days ago
Joanne Mewis commented on Hexitime- The Skill Exchange and Timebank for Improving Healthcare 1 month 5 days ago

Active Campaigns